Fresenius Reports Net Loss in Q4

In a recent report from Fresenius, the German health-care company disclosed a shift to a net loss for the fourth quarter due to the deconsolidation of Fresenius Medical Care from its accounts. Despite this, Fresenius anticipates growth in earnings and sales for the year 2024.

Q4 Results

• Net loss of 614 million euros compared to a net profit of 255 million euros in the previous year.
• Revenue totaled 5.68 billion euros, showing nearly no change from the year before. However, organically, revenue increased by 5%, driven by Fresenius Kabi pharmaceutical business.
• Operating profit before special items saw a 13% rise, reaching 634 million euros.

Analyst Expectations

Analysts had predicted an adjusted operating profit of 590.7 million euros and revenue of 5.80 billion euros for the fourth quarter.

Outlook for 2024 and Beyond

• Organically, revenue is expected to grow between 3% and 6% in 2024.
• EBIT is forecasted to increase by 4% to 8% at constant currency.
• The company has raised its cost-savings target for 2025 to 400 million euros, surpassing its previous goal of 350 million euros for 2023.

Fresenius remains optimistic about its future growth prospects despite the challenges faced in Q4.